[Therapy of primary brain tumors with segidrin].
The results of segidrin administration to 46 patients with malignant and 6 patients with benign tumors of the brain are presented. Pronounced therapeutic effect for the whole group was 63.5% and 73%, if partial regression of neurologic symptoms in the entire brain and separate foci is considered. These indexes for patients with malignant tumors only were 61 and 71.7%, respectively. Since segidrin has virtually no significant untoward side-effects, it is considered a most safe medicine for managing brain tumors. It is recommended in cases of inoperable tumor and for post-operative adjuvant chemotherapy with a view to extending the patient's survival time and improving the quality of life.
Filov
V A
VA
Gershanovich
M L
ML
Ivin
B A
BA
Danova
L A
LA
Gurchin
F A
FA
Naryshkin
A G
AG
Leshchinskiĭ
V I
VI
Zemskaia
A G
AG
Nikiforov
B M
BM
Breĭvis
P V
PV
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006834:Hydrazines; C029424:hydrazine